In addition, the association of EGFR, c‐Src activation‐induced CD47 Y288 phosphorylation and CD47 expression with aggravation of human GBM highlights the significance of this signaling axis in GBM tumor evasion and tumor development and accentuates the need to improve the current cancer therapy and eliminate drug resistance with a combination of CD47‐SIRPα blockade with RTK‐targeted treatment. This evidence concerns the gene CD47 and cancer.